Breast cancer progression after HER2 therapy
Anti-HER2 therapy no longer controls the disease. What needs to be reassessed?
After progression on HER2 therapy, HER2 status can be reassessed and the next choice depends on the sequence of therapy undertaken and the location of spread.
Not a diagnosis and not final medical advice. Must be reviewed by a doctor.
What changes at this stage
- HER2 status can change so re-examination is sometimes guided by taking a new sample.
- Brain involvement alters drug selection considerations.
- The order of previous drug categories influences subsequent choices.
Options that are usually discussed
Reassess marker status
Sampling from recent lesions may be performed to confirm HER2 status.
Next category
Antibody-drug conjugates and other combinations are discussed according to therapeutic history.
Treatment of brain involvement
In diseases with brain lesions, the choice of therapy is tailored to penetration into the central nervous system.
The decision remains with your doctor
Practical next steps
- Request reassessment of HER2 scores from recent samples whenever possible.
- Note the order of all anti-HER2 therapy that has been undertaken.
- Ask if there are clinical trials that screen for current marker status.
Questions for your oncologist
- Do HER2 scores need to be reassessed from newer samples?
- What categories of medications have I never taken?
- Is there brain involvement that changes choices?
- Are there appropriate clinical trials?
Relevant biomarkers
Treatment categories
Drugs commonly discussed
Would you like to discuss this situation with someone?
Send a request with the context from this page so the documents and questions to prepare can be identified sooner.
After submission, a human navigator reviews your request and contacts you through your chosen channel. The WhatsApp message already includes this page context, so you do not need to explain from the beginning.
Clinical data is not requested in the form and is not sent to analytics. Do not send medical reports through WhatsApp or email; use the secure upload page. We do not promise eligibility or any treatment outcome.
Next steps
These suggestions come from links between entries in TanyaKanker's database, not from a medical judgement. Each suggestion includes why it appears.
Next to learn
- Breast Cancer
Cancer type
Reason: Has a decision situation
- BRCA1 / BRCA2
Biomarker
Reason: Related through a biomarker
- HER2
Biomarker
Reason: Related through a biomarker
- Lung cancer with spread to the brain
Decision situation
Reason: Menyusul
- Olaparib
Drug
Reason: Related to this page
- Pertuzumab
Drug
Reason: Related to this page
To check
- Immunotherapy
Treatment category
Reason: Mungkin memerlukan
- Chemotherapy
Treatment category
Reason: Mungkin memerlukan
- SBRT (stereotactic radiotherapy)
Treatment category
Reason: Mungkin memerlukan
- Targeted therapy
Treatment category
Reason: Mungkin memerlukan
- Check medical report completeness
Tool
Reason: Prepare documents that still need confirmation
- Prepare questions for your doctor
Tool
Reason: Bring clear questions to the next conversation
What you can do
- Upload medical reports
Build a case summary in twelve steps
Reason: Often the most useful next step after reading this page
- Request a second opinion
Review of the treatment plan
Reason: Relevant when a treatment plan is being considered
- Consult a navigator
A request is recorded with this page context
Reason: For asking the next step directly
Recently updated
- Leukemia
Cancer page
Date: Data revision 2026-09-10
- Brain Cancer
Cancer page
Date: Data revision 2026-09-10
- Pancreatic Cancer
Cancer page
Date: Data revision 2026-09-10
- Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
NCT03191149 - Phase 2
Date: Registry update in the last 30 days (2026-10-15)
Want to follow changes on this topic? Save the page or follow the topic so it is easy to find again. View saved items.